ArticleMedicine2026
Plasma proteins and irritable bowel syndrome: A proteome-wide Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a complex disorder with unclear etiology and underlying mechanisms. This research aimed to identify possible plasma proteins linked to IBS using a proteome-wide Mendelian randomization (MR) analysis. We performed a bidirectional two-sample MR analysis to investigate the causal relationship between 4907 plasma proteins and IBS. Genetic data from 35,559 Icelanders and IBS genome-wide association study data from 329,381 individuals in the FinnGen consortium were used to select instrumental variables meeting stringent criteria. Several MR methods such as inverse variance weighted, MR-Egger, and Weighted Median, along with sensitivity analyses, were utilized to confirm the robustness of the findings. Enrichment analyses and gene interaction studies were also conducted to investigate biological pathways related to the significant findings. MR analysis identified 20 plasma proteins significantly associated with IBS. Of these, Scavenger Receptor Class A Member 5 and Fibroblast Growth Factor Binding Protein-1 were negatively associated with IBS, indicating a protective effect. The other 18 plasma proteins associated with IBS onset include but are not limited to Leucine-rich repeat kinase 2, Ras and Rab interactor 3, and Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, all of which showed a positive correlation with increased IBS risk. Reverse MR analysis revealed no evidence that IBS influences plasma protein expression, suggesting that these proteins may play a causal role in the development of IBS. Enrichment analyses highlighted significant involvement in mitochondrial processes, synaptic vesicle recycling, and endosomal transport. In summary, this study identified 20 plasma proteins as potential causal factors in the development of IBS. The findings suggest that these proteins could serve as therapeutic targets, offering new insights into the underlying mechanisms of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.